Avoidance of Insulin-induced Lipohypertophy in People With Diabetes Using Ultrasound Scanning Within Diabetes Clinics
NCT06782568 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2026-02-13
Summary
Diabetes is a common long-term health condition globally. Type 1 diabetes requires insulin treatment right from diagnosis. Similarly, many living with type 2 diabetes eventually require insulin injections as the condition progresses. A common but often underappreciated complication associated with insulin use is the formation of fatty tissue at injection sites, known as "Lipos," a shorthand for "Lipohypertrophy." These Lipos can interfere with insulin absorption, leading to an altered insulin action profile. This results in glucose fluctuations increasing the risk of both high and low glucose levels.
In current medical practice, Lipos are assessed through clinical examination, specifically by physically palpating the injection sites. Research indicates that approximately 40% of insulin-treated individuals may have Lipos. However, manual palpation can often overlook these fatty deposits. Ultrasound scanning (USS) presents a more effective method for detecting Lipos. Studies that have employed ultrasound scanning have reported a much higher prevalence, reaching up to 86%.
The primary goal of this study is to ascertain whether the avoidance of ultrasound-identified Lipos can improve glucose regulation. The focus will be on individuals using continuous glucose monitoring who exhibit high glucose fluctuations and less time within their target range. By focusing on this population, the chances of identifying those with Lipos will increase.
Participants will undergo a clinical examination followed by an ultrasound scan. Those found to have Lipos will receive guidance on avoiding those sites and education on insulin injection techniques. Glucose data will be collected periodically over the next 24 weeks. After this period, participants will return for a follow-up ultrasound scan. Additionally, members of the diabetes care team will be trained to conduct the ultrasound scans. Data from this study may also be utilized to develop artificial intelligence algorithms aimed at identifying Lipos in future ultrasound scans.
Conditions
- Type 1 Diabetes (T1D)
- Type 2 Diabetes, Insulin Requiring
Interventions
- DIAGNOSTIC_TEST
-
Ultrasound Scan
Participants will undergo an ultrasound scan of insulin injection sites at baseline and after 6 months.
Sponsors & Collaborators
-
Imperial College Healthcare NHS Trust
collaborator OTHER -
Imperial College London
lead OTHER
Principal Investigators
-
Lalantha Leelarathna, PhD FRCP · Imperial College London
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-01-01
- Primary Completion
- 2026-12-31
- Completion
- 2027-05-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
NCT02833415 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
NCT07012642 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
NCT04964388 ·Status: TERMINATED ·Phase: PHASE2
-
Effects of GLP-1 Agonists on Gastric Volume
NCT05854979 ·Status: COMPLETED
-
Glucolipotoxicity and Type 2 Diabetes
NCT01375270 ·Status: COMPLETED ·Phase: NA
-
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
NCT02777073 ·Status: COMPLETED ·Phase: NA
-
Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes
NCT03582956 ·Status: TERMINATED ·Phase: NA
-
Dynamics of Insulin Absorption in Subclinical Lipohypertrophy Using the Euglycemic Clamp Technique
NCT03229850 ·Status: WITHDRAWN ·Phase: NA
-
Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists
NCT06003985 ·Status: COMPLETED
-
Pilot Study to Assess the Effects of Hepatic Ultrasound Insonification on Subjects With T2DM
NCT04502212 ·Status: COMPLETED ·Phase: NA
-
Role of the Liver in Glucose Homeostasis Using Metabolic Imaging
NCT04352738 ·Status: COMPLETED
-
Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery
NCT01257087 ·Status: COMPLETED ·Phase: NA
-
Intermittent Fasting in Adults With Type 1 Diabetes
NCT06134986 ·Status: COMPLETED ·Phase: NA
-
Lipohypertrophy Monitoring Study
NCT04659330 ·Status: COMPLETED ·Phase: NA
-
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia
NCT00418288 ·Status: COMPLETED ·Phase: NA
-
Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes
NCT07156331 ·Status: NOT_YET_RECRUITING
-
Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging
NCT03498001 ·Status: COMPLETED ·Phase: NA
-
Regulation of Tissue Lipolysis by Insulin in Type 2 Diabetes
NCT01680133 ·Status: COMPLETED
-
Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)
NCT05946148 ·Status: COMPLETED
-
Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects
NCT03991299 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Regional Lipolysis Insulin Regulation
NCT06392854 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Prevalence of Overweight and Obesity in Adult Patients Suffering From Type 1 Diabetes
NCT05713448 ·Status: RECRUITING
-
Sleep Apnea in Type 1 Diabetes
NCT01935765 ·Status: COMPLETED ·Phase: NA
-
Hepatic Metabolic Changes in Response to Glucagon Infusion
NCT03526445 ·Status: COMPLETED ·Phase: NA
-
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
NCT02914886 ·Status: COMPLETED ·Phase: PHASE4